Similarly, Johnson et al. found that KRAS mutation was an independent factor associated with shorter survival because of inherent biological differences in KRAS-driven lung cancer rather than differences in receiving prolonging life treatments like platinum-based chemotherapy and bevacizumab [17]. Here, KRAS is linked to lung carcinoma.